Biologics and oral small-molecule inhibitors for treatment of pediatric atopic dermatitis: Opportunities and challenges

被引：4
作者：
Zhao, Anqi [1 ,2 ,3 ]
Pan, Chaolan [1 ,2 ]
Li, Ming [3 ,4 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Dermatol, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Inst Dermatol, Shanghai, Peoples R China
[3] Fudan Univ, Dept Dermatol, Childrens Hosp, Shanghai, Peoples R China
[4] Fudan Univ, Childrens Hosp, Dept Dermatol, Shanghai 200092, Peoples R China
来源：
PEDIATRIC INVESTIGATION | 2023年 / 7卷 / 03期
关键词：
Atopic dermatitis; Biologics; Clinical trials; Dupilumab; Pediatrics; Small-molecule inhibitors; DOUBLE-BLIND; PLACEBO; ADOLESCENTS; ANTIBODY; ADULTS; UPADACITINIB; DUPILUMAB; EFFICACY; CHILDREN; SAFETY;
D O I：
10.1002/ped4.12400
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Atopic dermatitis (AD) is a complex disease characterized by recurrent eczematous lesions and refractory pruritus that drastically impairs quality of life. Due to the chronic and relapsing course, patients are easily trapped in the debilitating condition. Classical therapies show limitations, especially for patients with moderate-to-severe phenotypes. Advanced new insights in targeted therapies exhibit great application prospects which were reinforced by the more profound understanding of the disease pathogenesis. However, the sustained efficiency, biosafety, and long-term benefits still remain in further exploration. This review summarizes recent clinical studies on oral small-molecule inhibitors and biological agents for pediatric AD patients, which provides the latest frontiers to clinicians. *image
引用
收藏
页码：177 / 190
页数：14
相关论文
共 90 条
  • [1] [Anonymous], 2022, Neuropsychologic assessments of dupilumab-treated adolescent participants with moderate-to-severe atopic dermatitis (NEURADAD)
  • [2] The molecular regulation of Janus kinase (JAK) activation
    Babon, Jeffrey J.
    Lucet, Isabelle S.
    Murphy, James M.
    Nicola, Nicos A.
    Varghese, Leila N.
    [J]. BIOCHEMICAL JOURNAL, 2014, 462 : 1 - 13
  • [3] Anti-IgE therapy and severe atopic dermatitis: A pediatric perspective
    Barrios, Jonathan Lacombe
    Begin, Philippe
    Paradis, Louis
    Hatami, Afshin
    Paradis, Jean
    Des Roches, Anne
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 69 (05) : 832 - 834
  • [4] Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
    Bieber, T.
    Thyssen, J. P.
    Reich, K.
    Simpson, E. L.
    Katoh, N.
    Torrelo, A.
    De Bruin-Weller, M.
    Thaci, D.
    Bissonnette, R.
    Gooderham, M.
    Weisman, J.
    Nunes, F.
    Brinker, D.
    Issa, M.
    Holzwarth, K.
    Gamalo, M.
    Riedl, E.
    Janes, J.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (02) : 476 - 485
  • [5] Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
    Blauvelt, Andrew
    Guttman-Yassky, Emma
    Paller, Amy S.
    Simpson, Eric L.
    Cork, Michael J.
    Weisman, Jamie
    Browning, John
    Soong, Weily
    Sun, Xian
    Chen, Zhen
    Kosloski, Matthew P.
    Kamal, Mohamed A.
    Delevry, Dimittri
    Chuang, Chien-Chia
    O'Malley, John T.
    Bansal, Ashish
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (03) : 365 - 383
  • [6] Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial
    Chan, Susan
    Cornelius, Victoria
    Cro, Suzie
    Harper, John I.
    Lack, Gideon
    [J]. JAMA PEDIATRICS, 2020, 174 (01) : 29 - 37
  • [7] JAK inhibitors in the treatment of atopic dermatitis
    Chovatiya, Raj
    Paller, Amy S.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 148 (04) : 927 - 940
  • [8] ClinicalTrials.gov, ClinicalTrials
  • [9] ClinicalTrials.gov, 2018, ClinicalTrials
  • [10] ClinicalTrials.gov, 2019, STUD BAR LY3009104 C
123456789